Evidence map›Paper›PMID 35154430›Full record

ArticleOncology letters2022

Extracts of

Harutoshi Matsumoto, Saeko Ando, Eri Yoshimoto, Takamasa Numano, Nahida Sultana, Katsumi Fukamachi, Munekazu Iinuma, Kensuke Okuda, Kazunori Kimura, Masumi Suzui

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Heliyon · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Harutoshi MatsumotoDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Saeko AndoDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Eri YoshimotoDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Takamasa NumanoResearch and Development Division, DIMS Institute of Medical Science, Ichinomiya, Aichi 491-0113, Japan.
Nahida SultanaDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Katsumi FukamachiDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Munekazu IinumaLaboratory of Pharmacognosy, Gifu Pharmaceutical University, Gifu-shi, Gifu 501-1196, Japan.
Kensuke OkudaLaboratory of Bioorganic and Natural Products Chemistry, Kobe Pharmaceutical University, Kobe, Hyogo 658-8558, Japan.
Kazunori KimuraDepartment of Clinical Pharmaceutics, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Masumi SuzuiDepartment of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467-8601, Japan.
Nagoya City University · JPGifu Pharmaceutical University · JPKobe Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cell cycle controlgrowth inhibitionhuman cancer cellsMusa basjootumor xenograft assay

Identifiers

PMID35154430
PMCPMC8822496
OpenAlexW4210896968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.